PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34042274-0	2021	Arsenic trioxide reduces the expression of E2F1, cyclin E, and phosphorylation of PI3K signaling molecules in acute leukemia cells.	Arsenic Trioxide	0-16	E2F transcription factor 1	Homo sapiens	43-47	
34042274-4	2021	We found that ATO inhibited the proliferation of APL cells through down-regulation of E2F1 and cyclin E expression, and stimulation of pRb.	Arsenic Trioxide	14-17	E2F transcription factor 1	Homo sapiens	86-90	
34042274-8	2021	Our findings demonstrate that ATO inhibits APL cell growth through reduced expression of E2F1, cyclin E, and stimulation of pRb.	Arsenic Trioxide	30-33	E2F transcription factor 1	Homo sapiens	89-93	
25574600-0	2015	E2F1-mediated FOS induction in arsenic trioxide-induced cellular transformation: effects of global H3K9 hypoacetylation and promoter-specific hyperacetylation in vitro.	Arsenic Trioxide	31-47	E2F transcription factor 1	Homo sapiens	0-4	
28927142-7	2017	In addition, treatment with ATO resulted in the downregulation of X-linked inhibitor of apoptosis, B-cell lymphoma-2 (Bcl-2), E2F transcription factor 1 (E2F1), thymidylate synthase and ribonucleotide reductase M1 in addition to the upregulation of Bcl-2 antagonist/killer protein, cleaved poly ADP-ribose polymerase and cleaved caspase 3 in a cell-line specific manner.	Arsenic Trioxide	28-31	E2F transcription factor 1	Homo sapiens	126-152	
28927142-7	2017	In addition, treatment with ATO resulted in the downregulation of X-linked inhibitor of apoptosis, B-cell lymphoma-2 (Bcl-2), E2F transcription factor 1 (E2F1), thymidylate synthase and ribonucleotide reductase M1 in addition to the upregulation of Bcl-2 antagonist/killer protein, cleaved poly ADP-ribose polymerase and cleaved caspase 3 in a cell-line specific manner.	Arsenic Trioxide	28-31	E2F transcription factor 1	Homo sapiens	154-158	
25574600-10	2015	CONCLUSION: Global H3K9 hypoacetylation and promoter-specific hyperacetylation facilitate E2F1-mediated FOS induction in As2O3-induced cellular transformation.	Arsenic Trioxide	121-126	E2F transcription factor 1	Homo sapiens	90-94	
25174355-0	2014	E2F1 downregulation by arsenic trioxide in lung adenocarcinoma.	Arsenic Trioxide	23-39	E2F transcription factor 1	Homo sapiens	0-4	
25335113-0	2015	Downregulation of thymidylate synthase and E2F1 by arsenic trioxide in mesothelioma.	Arsenic Trioxide	51-67	E2F transcription factor 1	Homo sapiens	43-47	
25335113-14	2015	In the H226 xenograft model, the relative tumor growth was aborted, and E2F1 was downregulated while cleaved caspase-3 was elevated and localized to the nucleus in the ATO treatment group.	Arsenic Trioxide	168-171	E2F transcription factor 1	Homo sapiens	72-76	
25174355-11	2014	Using the H358 xenograft model, the tumor growth was suppressed in the ATO treatment group during 8 days of treatment, associated with downregulation of E2F1 and upregulation of truncated Bid and cleaved caspase-3.	Arsenic Trioxide	71-74	E2F transcription factor 1	Homo sapiens	153-157	
25174355-12	2014	In conclusion, ATO has potent in vitro and in vivo activity in lung adenocarcinoma, partially mediated through E2F1 downregulation and apoptosis.	Arsenic Trioxide	15-18	E2F transcription factor 1	Homo sapiens	111-115